Following repeated legislative defeats to repeal the Affordable Care Act (ACA), President Trump is taking steps to further sabotage the ACA. This includes ending cost sharing reduction (CSR) payments to issuers and issuing an executive order that would destabilize the health care marketplace and erode patient protections.
Both actions would have devastating effects on people living with or at risk of HIV and STDs. Ending the $7 billion in CSR payments would serve to increase premiums and force the Ryan White HIV/AIDS Program to bear a greater share of insurance costs. It would drive insurance companies out of the state health care marketplaces and in turn, put the marketplaces out of business.
In addition to this action, President Trump signed an executive order that directs federal agencies to expand association health plans and short-term limited insurance. Such plans would not have to meet “essential health benefits,” virtually ensuring they will be useless for people with pre-existing conditions, including people living with HIV and STDs. The executive order creates the opportunity for younger and healthier people to exit the more regulated marketplaces and destabilize the entire insurance market
We urge the courts to end the illegal action to halt payment of the CSRs. We also call on Congress to quickly approve bipartisan legislation to stabilize the marketplace and extend CSR payments. People living with HIV and other STDs, particularly people of color, often face multiple barriers to accessing the care and treatment they need to stay healthy. The President’s actions would only strengthen these barriers, making it even more difficult for these communities most impacted by HIV to receive the care they need.
AIDS United (AU), NASTAD, the National Coalition of STD Directors (NCSD), NMAC, and The AIDS Institute (TAI) are national non-partisan, non-profit organizations focused on ending HIV in the U.S. They have been working in partnership to identify and share resources to sustain successes and progress we have made in HIV and STD prevention, care and treatment in the United States.